[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Tsukuda M, Kida A, Fujii M, Kono N, Yoshihara T, Hasegawa Y, Sugita M, Chemotherapy Study Group of Head and Neck Cancer: Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer; 2005 Oct 17;93(8):884-9
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer.
  • The purpose of this study was to determine the feasible adjuvant therapy administration schedule of S-1 for locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN).
  • Patients receiving definitive treatments were randomly assigned to either arm A (51 cases) receiving oral S-1 of 2-week administration followed by 1-week rest for 6 months, or arm B receiving S-1 of 4-week administration followed by 2-week rest for 6 months.
  • Planned treatment was given in 40% of patients in arm A and 29% in arm B.
  • The cumulative rates of the relative total administration dose of S-1 at 100% were 54.9% (95% CI: 40.1-69.7%) in arm A and 34.3% (95% CI: 21.1-47.4%) in arm B, respectively (P=0.054).
  • Adverse events were recorded in 41 patients (82.0%) in arm A and 48 patients (94.1%) in arm B (P=0.060).
  • The incidences of diarrhoea (10 vs 28%; P<0.05) and skin toxicities (18 vs 37%; P<0.05) were significantly higher in arm B.
  • One-year disease-free survival was similar in both arms: arm A 81.2% (95% CI: 70.0-92.4%); arm B 77.0% (95% CI: 65.0-89.0%).
  • The schedule of 2-week administration followed by 1-week rest seems to be more feasible for oral 6-month administration of S-1 in adjuvant chemotherapy of locoregionally advanced SCCHN.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Administration, Oral. Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Administration Schedule. Drug Combinations. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1743-52 [15117998.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] Gastric Cancer. 2004;7(2):104-9 [15224197.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1179-86 [15277256.001]
  • [Cites] J Clin Oncol. 1987 Jan;5(1):10-20 [2433406.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):838-47 [2185340.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(4):705-13 [1618662.001]
  • [Cites] Gan To Kagaku Ryoho. 1994 Jul;21(8):1169-77 [8031158.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2602-6 [8653704.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):181-5 [8630927.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] Br J Cancer. 2004 Nov 15;91(10):1769-74 [15505626.001]
  • [Cites] Gastric Cancer. 2005;8(1):6-11 [15747168.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2172-84 [15800310.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):141-5 [10901361.001]
  • [Cites] Gan To Kagaku Ryoho. 2001 Oct;28(10):1381-90 [11681245.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):995-1006 [12176777.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):412-8 [12518365.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1956-62 [15041712.001]
  • [Cites] Anticancer Drugs. 2004 Feb;15(2):85-106 [15075664.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • (PMID = 16189518.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  • [Other-IDs] NLM/ PMC2361656
  •  go-up   go-down


2. Klinghammer K, Knödler M, Schmittel A, Budach V, Keilholz U, Tinhofer I: Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res; 2010 Jan 1;16(1):304-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
  • PURPOSE: Cetuximab, a monoclonal antibody targeting epidermal growth factor receptor (EGFR), has shown clinical efficacy in squamous cell carcinoma of the head and neck with prolonged progression-free (PFS) and overall survival (OS).
  • In this study, we analyzed whether cetuximab-induced skin rash was correlated with distinct polymorphisms within the EGFR gene known to modulate EGFR expression, ligand binding, or signaling activity.
  • EXPERIMENTAL DESIGN: Fifty-one patients enrolled in a single-arm phase II multicenter study for second-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck with cetuximab/docetaxel were genotyped for two genetic variations in the EGFR gene, a point substitution G-->A in exon 13 resulting in an amino acid substitution in position 521 (EGFR-R521K) and a CA repeat (CA-SSR) polymorphism in intron 1.
  • Association between genotypes and incidence/grade of skin rash was determined by Fisher's exact test.
  • RESULTS: Overall, 21 patients (41%) developed skin rash with grade >1 within 6 weeks of treatment.
  • The common EGFR-R521K genotype (G/G) was significantly associated with increased skin toxicity (P = 0.024) and showed a trend toward reduced risk of tumor progression (hazard ratio, 0.55; 95% confidence interval, 0.27-1.08; P = 0.08), whereas no correlation of the EGFR-R521K genotype with OS could be observed (P = 0.20).
  • No significant interaction between CA-SSR polymorphism and skin toxicity, PFS, or OS could be detected.
  • CONCLUSIONS: Our study revealed an influence of the EGFR-R521K genotype on skin toxicity and suggested its relation to clinical activity of cetuximab/docetaxel treatment.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / genetics. Exanthema / chemically induced. Exanthema / genetics. Genes, erbB-1. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / genetics. Polymorphism, Genetic
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cetuximab. Disease-Free Survival. Female. Humans. Male. Middle Aged. Survival Analysis. Taxoids / administration & dosage. Taxoids / adverse effects. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Rashes.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20028750.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Taxoids; 15H5577CQD / docetaxel; PQX0D8J21J / Cetuximab
  •  go-up   go-down


3. Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, Kang S, Linden KG, Heffernan M, Duvic M, Richmond E, Elewski BE, Umar A, Bell W, Gordon GB: Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst; 2010 Dec 15;102(24):1835-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.
  • BACKGROUND: Preclinical studies indicate that the enzyme cyclooxygenase 2 plays an important role in ultraviolet-induced skin cancers.
  • We evaluated the efficacy and safety of celecoxib, a cyclooxygenase 2 inhibitor, as a chemopreventive agent for actinic keratoses, the premalignant precursor of nonmelanoma skin cancers, and for nonmelanoma skin cancers, including cutaneous squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs).
  • Subjects were evaluated at 3, 6, 9 (ie, completion of treatment), and 11 months after randomization.
  • The primary endpoint was the number of new actinic keratoses at the 9-month visit as a percentage of the number at the time of randomization.
  • In exploratory analyses, we evaluated the number of nonmelanoma skin cancers combined and SCCs and BCCs separately per patient at 11 months after randomization using Poisson regression, after adjustment for patient characteristics and time on study.
  • The numbers of adverse events in the two treatment arms were compared using χ(2) or Fisher exact tests.
  • However, at 11 months after randomization, there were fewer nonmelanoma skin cancers in the celecoxib arm than in the placebo arm (mean cumulative tumor number per patient 0.14 vs 0.35; rate ratio [RR] = .43, 95% confidence interval [CI] = 0.24 to 0.75; P = .003).
  • After adjusting for age, sex, Fitzpatrick skin type, history of actinic keratosis at randomization, nonmelanoma skin cancer history, and patient time on study, the number of nonmelanoma skin cancers was lower in the celecoxib arm than in the placebo arm (RR = 0.41, 95% CI = 0.23 to 0.72, P = .002) as were the numbers of BCCs (RR = 0.40, 95% CI = 0.18 to 0.93, P = .032) and SCCs (RR = 0.42, 95% CI = 0.19 to 0.93, P = .032).
  • CONCLUSIONS: Celecoxib may be effective for prevention of SCCs and BCCs in individuals who have extensive actinic damage and are at high risk for development of nonmelanoma skin cancers.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]
  • [Cites] J Invest Dermatol. 1994 Jun;102(6):4S-5S [8006434.001]
  • [Cites] J Invest Dermatol. 2000 Aug;115(2):273-7 [10951246.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):7-11 [11241303.001]
  • [Cites] Lancet. 2001 Mar 24;357(9260):926-9 [11289350.001]
  • [Cites] Arch Dermatol. 2001 Aug;137(8):1055-8 [11493098.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5 Suppl 4):37-51 [12102579.001]
  • [Cites] Photochem Photobiol. 2002 Jul;76(1):73-80 [12126310.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1105-8 [14578151.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):920-7 [15184247.001]
  • [Cites] J Drugs Dermatol. 2004 Jul-Aug;3(4):401-7 [15303784.001]
  • [Cites] Br J Dermatol. 1994 Oct;131(4):455-64 [7947197.001]
  • [Cites] Arch Dermatol. 1995 Feb;131(2):170-5 [7857113.001]
  • [Cites] Int J Cancer. 1995 Jul 17;62(2):165-9 [7622291.001]
  • [Cites] Br J Cancer. 1996 Oct;74(8):1302-7 [8883422.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):957-61 [9367070.001]
  • [Cites] Carcinogenesis. 1998 May;19(5):723-9 [9635856.001]
  • [Cites] Br J Dermatol. 1998 Dec;139(6):1033-9 [9990367.001]
  • [Cites] Mol Carcinog. 1999 Aug;25(4):231-40 [10449029.001]
  • [Cites] Lancet. 1999 Aug 28;354(9180):723-9 [10475183.001]
  • [Cites] Carcinogenesis. 1999 Oct;20(10):1939-44 [10506108.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944.001]
  • [Cites] Br J Dermatol. 2005 Mar;152(3):518-23 [15787821.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):681-90 [16091570.001]
  • [Cites] J Exp Med. 2005 Oct 3;202(7):931-9 [16186186.001]
  • [Cites] J Am Acad Dermatol. 2005 Dec;53(6):966-72 [16310056.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):682-6 [16496410.001]
  • [Cites] J Am Acad Dermatol. 2006 Sep;55(3):490-500 [16908356.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2546-8 [17132769.001]
  • [Cites] N Engl J Med. 2007 Jul 26;357(4):360-9 [17652651.001]
  • [Cites] Mol Carcinog. 2007 Aug;46(8):692-8 [17443745.001]
  • [Cites] Mol Carcinog. 2007 Dec;46(12):981-92 [17583568.001]
  • [Cites] Photochem Photobiol. 2008 Mar-Apr;84(2):463-76 [18248498.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5 Suppl 2):S129-32 [18410798.001]
  • [Cites] Circulation. 2008 Apr 22;117(16):2104-13 [18378608.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Jun;66(3):208-17 [18304833.001]
  • [Cites] Mol Cancer Res. 2008 Jun;6(6):1003-16 [18567804.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Jun;1(1):21-31 [19138933.001]
  • [Cites] J Invest Dermatol. 2009 Apr;129(4):1016-25 [18843292.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2009 Apr;18(4):276-83 [19226541.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Jan;3(1):25-34 [20051370.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Jan;3(1):35-47 [20051371.001]
  • [Cites] Arch Dermatol. 2010 Mar;146(3):283-7 [20231499.001]
  • [Cites] Arch Dermatol. 2010 Apr;146(4):388-95 [20157019.001]
  • [Cites] Australas J Dermatol. 1983 Aug;24(2):79-82 [6661117.001]
  • [Cites] N Engl J Med. 1988 Jun 23;318(25):1633-7 [3287161.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 4;84(5):328-32 [1738183.001]
  • [Cites] JAMA. 1992 Jun 24;267(24):3305-10 [1597912.001]
  • [Cites] N Engl J Med. 1993 Oct 14;329(16):1147-51 [8377777.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1272-5 [8145782.001]
  • [CommentIn] J Natl Cancer Inst. 2010 Dec 15;102(24):1815-7 [21115881.001]
  • [CommentIn] Arch Dermatol. 2012 May;148(5):638-40 [22782153.001]
  • (PMID = 21115882.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-85183; United States / NIAMS NIH HHS / AR / P30 AR050948; United States / NCI NIH HHS / CA / P30 CA013148
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; JCX84Q7J1L / Celecoxib
  • [Other-IDs] NLM/ PMC3001966
  •  go-up   go-down


Advertisement
4. Ciocca O, Vassallo C, Brazzelli V, Fiandrino G, Rosso R, Borroni G: Sporotrichoid metastases to the skin from cutaneous squamous cell carcinoma in an immunocompetent patient. Am J Dermatopathol; 2010 Jun;32(4):395-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporotrichoid metastases to the skin from cutaneous squamous cell carcinoma in an immunocompetent patient.
  • Squamous cell carcinoma (SCC) of the skin may metastasize in more than 5% of cases.
  • The skin is rarely involved by metastases of SCC of the skin.
  • The case of a 70-year-old immunocompetent patient, with an ulcerated primary SCC on his right palm and 3 nodules in a linear array on his right arm is described.
  • The patient had been previously treated with chemotherapy and radiotherapy in another Department, with no benefit.
  • Despite right arm amputation and homolateral axillary lymphadenectomy, the patient died 4 months after a procedure, for pulmonary embolism.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Skin Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Aged. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arm / pathology. Cisplatin / administration & dosage. Fatal Outcome. Fluorouracil / administration & dosage. Hand / pathology. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Paclitaxel / therapeutic use. Radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495388.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


5. Brewster AM, Lee JJ, Clayman GL, Clifford JL, Reyes MJ, Zhou X, Sabichi AL, Strom SS, Collins R, Meyers CA, Lippman SM: Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol; 2007 May 20;25(15):1974-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma.
  • PURPOSE: To conduct a phase III trial of adjuvant 13-cis-retinoic acid (13cRA) plus interferon alfa (IFN-alpha) for preventing tumor recurrence and second primary tumors (SPTs) of skin squamous cell carcinoma (SCC) among patients with aggressive skin SCC.
  • PATIENTS AND METHODS: Sixty-six patients with aggressive skin SCC were randomly assigned to receive either 6 months of combined 13cRA (1 mg/kg/d orally) and IFN-alpha (3 x 10(6) U subcutaneously three times per week) or no adjuvant therapy (control group) after SCC surgery and/or radiation.
  • RESULTS: At 21.5 months median follow-up, treatment did not improve the time to tumor recurrence and SPT versus control (hazard ratio [HR], 1.13; 95% CI, 0.53 to 2.41), time to tumor recurrence (HR, 1.08; 95% CI, 0.43 to 2.72), or time to SPT (HR, 0.89; 95% CI, 0.27 to 2.93).
  • Adjuvant 13cRA and IFN-alpha was moderately tolerable; 29% of patients in the treatment arm required dose reductions for grade 3 or 4 toxicities.
  • CONCLUSION: Results of this phase III trial do not support 13cRA plus IFN-alpha for adjuvant therapy of aggressive skin SCC.
  • With high rates of tumor recurrence and SPTs, patients with aggressive skin SCC continue to have an unmet medical need, with devastating mortality, morbidity, and financial consequences.
  • Promising agents with preclinical and early clinical results relevant to aggressive skin SCC deserve a high priority for future clinical drug development.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Neoplasm Recurrence, Local / prevention & control. Neoplasms, Second Primary / prevention & control. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Interferon-alpha / administration & dosage. Isotretinoin / administration & dosage. Male. Middle Aged. Prognosis. Prospective Studies. Recombinant Proteins. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 May 20;25(15):1953-4 [17513800.001]
  • (PMID = 17513803.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / P01-5P01CA68233
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; EH28UP18IF / Isotretinoin
  •  go-up   go-down


6. Kimmritz J, Hermes B, Schewe C, Haas N: [Squamous cell carcinoma in lupus vulgaris]. J Dtsch Dermatol Ges; 2004 Feb;2(2):116-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma in lupus vulgaris].
  • [Transliterated title] Carcinoma in lupo.
  • Lupus vulgaris and carcinoma in lupo have become rare events that take place in the developed countries only under special circumstances.
  • A 53-year-old woman developed such a carcinoma.
  • The diagnosis of lupus vulgaris was confirmed by biopsy when an erythematous lesion on her arm that had been present for 25 years enlarged and subsequently ulcerated.
  • Chemotherapy was discontinued because of lack of compliance and the ulcer grew markedly over the following 16 months.
  • Histology showed a squamous cell carcinoma within the ulcer.
  • Neither further systemic manifestations of tuberculosis nor metastases of the carcinoma were found.
  • Under continuous combined antituberculous therapy, the patient remained free of symptoms.
  • It also shows that alcoholism is a risk factor for tuberculosis, along with debilitating diseases such as lymphoma and AIDS as well as immunosuppressive therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Lupus Vulgaris / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Alcoholism / complications. Biopsy. Cell Transformation, Neoplastic / pathology. Comorbidity. Epithelium / pathology. Female. Humans. Middle Aged. Skin / pathology. Skin Ulcer / diagnosis. Skin Ulcer / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16279246.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. Haddad R, Sonis S, Posner M, Wirth L, Costello R, Braschayko P, Allen A, Mahadevan A, Flynn J, Burke E, Li Y, Tishler RB: Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer; 2009 Oct 1;115(19):4514-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A randomized phase 2 study was performed to investigate the efficacy/toxicity of combining concomitant boost radiation and weekly carboplatin/paclitaxel with or without amifostine in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
  • All patients were randomized to subcutaneous daily amifostine at a dose of 500 mg (Arm A) or no amifostine (Arm B).
  • To evaluate the correlation between serum cytokine levels and the severity of oral mucositis, we evaluated a subset (13 patients in Arm A and 11 patients in Arm B) of subjects at baseline and then on alternate weeks.
  • RESULTS: Fifty-eight patients were enrolled, 29 in each arm.
  • Major toxicities encountered were similar in both arms and included grade 3 (as determined by Common Terminology Criteria for Adverse Events, version 3.0) mucositis (75% in Arm A and 70% in Arm B) and grade 2 xerostomia (41% in both arms).
  • The median number of amifostine doses delivered was 28, with skin toxicity (grade 3 in 11 patients) as the limiting factor.
  • The median follow-up was 34 months, and only 5 failures had been encountered (2 local and 3 distant) at the time of last follow-up, with an overall survival rate of 89%.
  • Neck dissection was performed in 25 patients; 5 patients demonstrated persistent disease and 4 patients were alive without disease recurrence at the time of last follow-up.
  • The median time to percutaneous endoscopic gastrostomy removal was 9.6 months in Arm A and 10.4 months in Arm B.
  • Only 1 patient remained percutaneous endoscopic gastrostomy-dependent at the time of last follow-up.
  • The time to percutaneous endoscopic gastrostomy removal was prolonged.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Amifostine / administration & dosage. Amifostine / pharmacology. Carboplatin / administration & dosage. Combined Modality Therapy. Cytokines / blood. Disease-Free Survival. Female. Humans. Injections, Subcutaneous. Male. Middle Aged. Paclitaxel / administration & dosage. Radiotherapy Dosage. Stomatitis / etiology. Stomatitis / prevention & control. Survival Rate. Xerostomia / etiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 American Cancer Society.
  • (PMID = 19634161.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; BG3F62OND5 / Carboplatin; M487QF2F4V / Amifostine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


8. William WN Jr, Lee JL, Shin DM, Hong WK, Liu S, Lee JJ, Lippman SM, Khuri FR, Kim ES: Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. Am J Clin Oncol; 2009 Feb;32(1):15-9
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: In this single-arm, open label, dose-escalation study, we administered topotecan (0.75-1.5 mg/m) and gemcitabine (1000 mg/m) on days 1, 8, and 15 every 4 weeks to 25 patients with advanced solid tumors.
  • Other common grades 3-4 adverse events across all cohorts included non-neutropenic infections, fatigue, skin reactions, vomiting, and fever.
  • One partial response and 2 stable diseases were observed in patients with nasopharyngeal carcinoma.
  • Disease stabilization was also observed in patients with squamous cell carcinoma of the head and neck (3), nonsmall cell lung cancer (1), and thymoma (1).
  • Efficacy results support the further evaluation of this regimen in patients with head and neck cancer (particularly nasopharyngeal carcinoma).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Prognosis. Topotecan / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194117.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 7M7YKX2N15 / Topotecan; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


9. Corvò R, Benasso M, Sanguineti G, Lionetto R, Bacigalupo A, Margarino G, Pallestrini E, Merlano M, Vitale V, Rosso R: Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck: results from a phase III randomized trial. Cancer; 2001 Dec 1;92(11):2856-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck: results from a phase III randomized trial.
  • BACKGROUND: The authors previously have found that in patients with locally advanced squamous cell carcinoma of the head and neck (SCC-HN), alternating chemoradiotherapy (ALT) was superior to low-total-dose conventional radiotherapy alone.
  • They were randomly assigned to chemotherapy consisting of 4 cycles of intravenous cisplatin (20 mg/m(2) of body surface area per day for 5 consecutive days) and 5-fluorouracil (200 mg/m(2) per day for 5 consecutive days; weeks 1, 4, 7, and 10) alternated with three 2-week courses of radiotherapy (20 grays [Gy] per course, 2 Gy per day, 5 days per week; ALT, 70 patients) or to partly accelerated radiotherapy with final concomitant boost technique (75 Gy/40 fractions in 6 weeks; partly accelerated radiotherapy [PA-RT], 66 patients).
  • RESULTS: At the median follow-up of 60 months (range, 30-102 months), no statistical differences were observed in overall survival, progression free survival, or locoregional control between the 2 treatments.
  • The median overall survival and progression free survival were 24 and 15 months, respectively, in the ALT arm and 18 and 11 months, respectively, in PA-RT arm.
  • Patients treated in the PA-RT arm experienced higher Grade 3+ (World Health Organization) acute skin and mucosal reactions than patients in the ALT arm.
  • Moreover, local late mucosal and skin toxicities occurred more often in patients treated with PA-RT.
  • Therefore, definitive conclusions could not be made.
  • However, acute skin effects and late mucosal and skin toxicities above the clavicles appeared to be significantly lower with chemoradiotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Neoplasms, Second Primary / etiology. Patient Compliance. Regression Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11753959.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


10. Olmi P, Crispino S, Fallai C, Torri V, Rossi F, Bolner A, Amichetti M, Signor M, Taino R, Squadrelli M, Colombo A, Ardizzoia A, Ponticelli P, Franchin G, Minatel E, Gobitti C, Atzeni G, Gava A, Flann M, Marsoni S: Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial. Int J Radiat Oncol Biol Phys; 2003 Jan 1;55(1):78-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial.
  • PURPOSE: To compare conventional fractionation radiation therapy (RT), Arm A, vs. split-course accelerated hyperfractionated RT (S-AHF), Arm B, vs. conventional fractionation RT plus concomitant chemotherapy (CT), Arm C, in terms of survival and toxicity for advanced, unresectable epidermoid tumors of oropharynx.
  • METHODS AND MATERIALS: Between January 1993 and June 1998, 192 previously untreated patients affected with Stage III and IV oropharyngeal carcinoma (excluding T1N1 and T2N1) were accrued in a multicenter, randomized Phase III trial (ORO 93-01).
  • For Arms A and C, 66-70 Gy in 33-35 fractions, 5 days a week, were administered in 6.5-7 weeks to tumor and positive nodes.
  • In Arm B, the dose delivered to tumor and involved nodes was 64-67.2 Gy, giving 2 fractions of 1.6 Gy every day with an interfraction interval of at least 4 h and preferably 6 h, 5 days a week.
  • At 38.4 Gy, a 2-week split was planned; after the split, RT was resumed with the same modality.
  • In Arm C, CT regimen consisted of carboplatin and 5-fluorouracil (CBDCA 75 mg/m(2), Days 1-4; 5-FU 1,000 mg/m(2) i.v. over 96 h, Days 1-4, recycling every 28 days (at 1st, 5th, and 9th week).
  • RESULTS: No statistically significant difference was detected in overall survival (p = 0.129): 40% Arm A vs. 37% Arm B vs. 51% Arm C were alive at 24 months.
  • Similarly, there was no statistically significant difference in terms of event-free survival (p = 0.196): 20% for Arm A, 19% for Arm B, and 37% for Arm C were event free at 24 months.
  • On the contrary, the 2-year disease-free survival was significantly different among the three arms (p = 0.022), with a superiority for Arm C.
  • At 24 months, the proportion of patients without relapse was 42% for Arm C vs. 23% for Arm A and 20% for Arm B.
  • Patients in Arm A less frequently developed G3+ acute mucositis than their counterparts in Arm B or C (14.7% vs. 40.3% vs. 44%).
  • Arm C showed slightly more G3+ skin, s.c. tissue, and mucosal late side effects (RTOG scale), although significant sequelae were relatively uncommon, and mucosal sequelae were most commonly transient.
  • The occurrence of persistent G3 xerostomia was comparable in all three treatment arms.
  • CONCLUSIONS: The combination of simultaneous CT and RT with the regimen of this trial is better than RT alone in advanced oropharyngeal squamous-cell carcinomas, by increasing disease-free survival.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Combined Modality Therapy. Dose Fractionation. Female. Humans. Male. Middle Aged. Neoplasm Staging. Palliative Care. Patient Compliance. Radiotherapy / adverse effects. Salvage Therapy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12504039.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Duffaud F, Borner M, Chollet P, Vermorken JB, Bloch J, Degardin M, Rolland F, Dittrich C, Baron B, Lacombe D, Fumoleau P, EORTC-New Drug Development Group/New Drug Development Program: Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study. Eur J Cancer; 2004 Dec;40(18):2748-52
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
  • The purpose of this study was to evaluate the activity and safety of OSI-211, the liposomal form of lurtotecan, in patients ineligible for curative surgery or radiotherapy and with metastatic/locoregional recurrent squamous cell carcinoma of the head and neck (SCCHN) and target lesions either within a previously irradiated field ("within") or outside a previously irradiated field ("outside").
  • From July 2001 to March 2002, 32 patients from 14 institutions were enrolled in the "within" arm and 18 in the "outside" arm.
  • In the "within" arm, two patients were ineligible because their tumour site was not allowed in the protocol (nasopharynx, skin) and two other patients never started treatment.
  • Of the 46 eligible patients who started treatment, there was one objective response (response rate: 2.2% (95% Confidence Interval (CI): [0-11.5%]).
  • Twelve patients in the "within" arm and 6 in the "outside" arm had stable disease, with a median duration of 18 weeks, 95% CI (12.7-25.7).
  • The median time to progression was 6 weeks (95%CI: [5.9-12.7] weeks).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15571957.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4J1L80T08I / lurtotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


12. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrão Miziara JE, Balint B, De Marinis F, Keller A, Arén O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N: Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol; 2010 Apr 10;28(11):1835-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
  • PURPOSE This phase III, multicenter, randomized, placebo-controlled trial assessed the efficacy and safety of sorafenib, an oral multikinase inhibitor, in combination with carboplatin and paclitaxel in chemotherapy-naïve patients with unresectable stage IIIB or IV non-small-cell lung cancer (NSCLC).
  • PATIENTS AND METHODS Nine hundred twenty-six patients were randomly assigned to receive up to six 21-day cycles of carboplatin area under the curve 6 and paclitaxel 200 mg/m(2) (CP) on day 1, followed by either sorafenib 400 mg twice a day (n = 464, arm A) or placebo (n = 462, arm B) on days 2 to 19.
  • RESULTS Overall demographics were balanced between arms; 223 patients (24%) had squamous cell histology.
  • On the basis of a planned interim analysis, median OS was 10.7 months in arm A and 10.6 months in arm B (hazard ratio [HR] = 1.15; 95% CI, 0.94 to 1.41; P = .915).
  • A prespecified exploratory analysis revealed that patients with squamous cell histology had greater mortality in arm A than in arm B (HR = 1.85; 95% CI, 1.22 to 2.81).
  • Main grade 3 or 4 sorafenib-related toxicities included rash (8.4%), hand-foot skin reaction (7.8%), and diarrhea (3.5%).
  • CONCLUSION No clinical benefit was observed from adding sorafenib to CP chemotherapy as first-line treatment for NSCLC.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Benzenesulfonates / administration & dosage. Carboplatin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Staging. Niacinamide / analogs & derivatives. Paclitaxel / administration & dosage. Phenylurea Compounds. Placebos. Pyridines / administration & dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Apr 10;28(11):1810-2 [20212244.001]
  • (PMID = 20212250.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Placebos; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


13. Vervenne WL, Bollen JM, Bergman JJ, Nio CY, Hulshof MC, Van Lanschot JJ, Richel DJ: Evaluation of the antitumor activity of gefitinib (ZD1839) in combination with celecoxib in patients with advanced esophageal cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):4054

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4054 Background: The epidermal growth factor receptor (EGFR) is highly expressed in esophageal cancer and is associated with advanced disease, resistance to chemotherapy and radiotherapy, and poor prognosis.
  • In preclinical studies, COX2 inhibition decreased cell growth and increased apoptosis in esophageal cancer cells (Cancer Res 2000; 60: 5767-72).
  • In this study, we examined the efficacy and tolerability of the combination of the orally active EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) with the COX2 inhibitor celecoxib (Celebrex) in patients with advanced esophageal cancer without previous exposure to chemotherapy.
  • METHODS: In this single-arm Phase II trial, patients received gefitinib (250 mg/day) and celecoxib (400 mg bid).
  • RESULTS: To date, 15 patients have been recruited; 3 with squamous-cell carcinoma and 12 with adenocarcinoma.
  • At first evaluation after 2 months of treatment, 10 patients (71%) had disease progression while 3 (21%) had stable disease and are in follow-up with a mean time of 5.5 months.
  • The most frequently occurring adverse event was acneiform skin rash, grade 1/2 in 6 patients (40%).
  • No treatment-related grade 3/4 toxicities were seen.
  • CONCLUSIONS: Combination treatment with gefitinib and celecoxib was generally well tolerated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014415.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Blumenschein GR Jr, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M: Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol; 2009 Sep 10;27(26):4274-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
  • We evaluated the antitumor response and tolerability of sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer (NSCLC), most of whom had received prior platinum-based chemotherapy.
  • PATIENTS AND METHODS: This was a phase II, single-arm, multicenter study.
  • Patients with relapsed or refractory advanced NSCLC received sorafenib 400 mg orally twice daily until tumor progression or an unacceptable drug-related toxicity occurred.
  • The predominant histologies were adenocarcinoma (54%) and squamous cell carcinoma (31%).
  • Four patients with SD developed tumor cavitation.
  • Major grades 3 to 4, treatment-related toxicities included hand-foot skin reaction (10%), hypertension (4%), fatigue (2%), and diarrhea (2%).
  • Nine patients died within a 30-day period after discontinuing sorafenib, and one patient experienced pulmonary hemorrhage that was considered drug related.
  • CONCLUSION Continuous treatment with sorafenib 400 mg twice daily was associated with disease stabilization in patients with advanced NSCLC.
  • The broad activity of sorafenib and its acceptable toxicity profile suggest that additional investigation of sorafenib as therapy for patients with NSCLC is warranted.
  • [MeSH-major] Benzenesulfonates / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Diarrhea / chemically induced. Drug Resistance, Neoplasm. Fatigue / chemically induced. Female. Humans. Male. Middle Aged. Nausea / chemically induced. Neoplasm Recurrence, Local. Niacinamide / analogs & derivatives. Phenylurea Compounds. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652055.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00101413
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


15. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Calais G: Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol; 2004 Jan 1;22(1):69-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma.
  • PURPOSE: We report the 5-year survival and late toxicity results of a randomized clinical trial, which showed a 3-year improvement in overall survival and locoregional control of stage III or IV oropharynx carcinoma, using concomitant radiochemotherapy (arm B), compared with standard radiotherapy (arm A).
  • PATIENTS AND METHODS: A total of 226 patients were entered onto a phase III multicenter randomized trial comparing radiotherapy alone (70 Gy in 35 fractions; arm A) with concomitant radiochemotherapy (70 Gy in 35 fractions with three cycles of a 4-day regimen comprising carboplatin and fluorouracil; arm B).
  • Five-year late toxicity was evaluated using National Cancer Institute Common Toxicity Criteria for neurological toxicity, hearing, taste, mandibula, and teeth damage, and Radiation Therapy Oncology Group toxicity criteria for skin, salivary gland, and mucosa.
  • RESULTS: Five-year overall survival, specific disease-free survival, and locoregional control rates were 22% and 16% (log-rank P =.05), 27% and 15% (P =.01), and 48% and 25% (P =.002), in arm B and arm A, respectively.
  • Stage IV, hemoglobin level lower than 125 g/L, and standard treatment were independent prognostic factors of short survival and locoregional failure by univariate and multivariate analysis.
  • One or more grade 3 to 4 complications occurred in 56% of the patients in arm B, compared with 30% in arm A (P was not significant).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Injections, Intravenous. Male. Middle Aged. Neoplasm Staging. Prognosis

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2004 Jan 1;22(1):19-22 [14657230.001]
  • (PMID = 14657228.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Lin WC, Chiu CH, Liou JL, Chen YM, Perng RP, Tsai CM: Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. Lung Cancer; 2006 Nov;54(2):193-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer.
  • PURPOSE: This phase II single arm, open label study was designed to evaluate the efficacy and toxicity of oral gefitinib (250mg) daily in previously untreated patients with advanced non-small-cell lung cancer (NSCLC).
  • Responses were assessed after every 8 weeks of therapy.
  • The most commonly seen adverse events (AEs) were skin toxicity (54.7%), diarrhea (43.4%) and nail change (16.9%).
  • Drug-related interstitial pneumonia was clinically diagnosed in four cases (7.5%).
  • CONCLUSIONS: Oral gefitinib, as compared to conventional chemotherapy, has comparable effect but less toxicity as a first-line treatment in Chinese patients who have advanced NSCLC, especially in those with adenocarcinoma histology.
  • A further phase III prospective study comparing gefitinib to standard chemotherapy to define the efficacy of gefitinib is appropriate in advanced NSCLC patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Aged. Asian Continental Ancestry Group. Disease-Free Survival. Female. Humans. Male. Neoplasm Staging. Prognosis. Survival Rate


17. Bardet E, Martin L, Calais G, Tuchais C, Bourhis J, Rhein B, Feham N, Alphonsi M: Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol; 2002 Dec;29(6 Suppl 19):57-60
Hazardous Substances Data Bank. AMIFOSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A prospective randomized study is comparing intravenous (IV; arm A) versus subcutaneous (SC; arm B) administration of amifostine in patients receiving radiotherapy for head and neck cancer.
  • Main eligibility criteria were newly diagnosed squamous cell head and neck cancer, inclusion of at least 75% of both parotid glands within radiation fields that would receive at least 40 Gy, and no evidence of distant metastasis.
  • Prophylactic use of pilocarpine and concomitant chemotherapy were prohibited.
  • Antiemetic treatment and blood pressure monitoring are required in both arms.
  • Acute toxicity included nausea/vomiting (12% for arm A; 13% for arm B), hypotension (6% in arm A; 0% in arm B), skin rash (15% in arm A; 16% in arm B), and asthenia (4% in arm A; 0% in arm B).
  • Compliance with amifostine administration was 70% in arm A (IV) and 80% in arm B (SC).
  • The rate of acute xerostomia (> or = grade 2) was 23% in arm A and 19% in arm B.
  • [MeSH-major] Amifostine / administration & dosage. Carcinoma, Squamous Cell / radiotherapy. Cytoprotection. Head and Neck Neoplasms / radiotherapy. Radiation-Protective Agents / administration & dosage

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA). All rights reserved.
  • (PMID = 12577246.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Protective Agents; M487QF2F4V / Amifostine
  •  go-up   go-down


18. Lutz BS: Aesthetic and functional advantages of the anterolateral thigh flap in reconstruction of tumor-related scalp defects. Microsurgery; 2002;22(6):258-64
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eight patients presented with tumor recurrences after previous surgery, irradiation, and/or chemotherapy.
  • Free flaps employed for reconstruction included antero-lateral thigh flaps (8), suprafascial radial forearm flap (1), lateral arm flap (1), latissimus dorsi muscle flap (1), and myocutaneous vertical rectus abdominis flap (1).
  • Other procedures included nerve grafts to the facial nerve (2), ectropion correction (2), and fascia lata slings for static procedure in facial palsy (2).
  • [MeSH-major] Head and Neck Neoplasms / surgery. Reconstructive Surgical Procedures / methods. Scalp / surgery. Skin Neoplasms / surgery. Soft Tissue Injuries / surgery. Surgical Flaps
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Sarcoma / surgery. Thigh. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12375293.001).
  • [ISSN] 0738-1085
  • [Journal-full-title] Microsurgery
  • [ISO-abbreviation] Microsurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, Eastern Cooperative Oncology Group: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol; 2005 Dec 1;23(34):8646-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Therapy of recurrent/metastatic squamous cell carcinoma of the head and neck results in median progression-free survival (PFS) of 2 months.
  • PATIENTS AND METHODS: Patients with recurrent/metastatic squamous cell carcinoma of the head and neck were randomly assigned to receive cisplatin every 4 weeks, with weekly cetuximab (arm A) or placebo (arm B).
  • Tumor tissue was assayed for EGFR expression by immunohistochemistry.
  • Median PFS was 2.7 months for arm B and 4.2 months for arm A.
  • The hazard ratio for progression of arm A to arm B was 0.78 (95% CI, 0.54 to 1.12).
  • Median overall survival was 8.0 months for arm B and 9.2 months for arm A (P = .21).
  • The hazard ratio for survival by skin toxicity in cetuximab-treated patients was 0.42 (95% CI, 0.21 to 0.86).
  • Objective response rate was 26% [corrected] for arm A and 10% [corrected] for arm B (P = .03).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Cetuximab. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cross-Over Studies. Dose-Response Relationship, Drug. Drug Hypersensitivity / etiology. Female. Follow-Up Studies. Hematologic Diseases / chemically induced. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Receptor, Epidermal Growth Factor / biosynthesis. Severity of Illness Index. Skin Diseases / chemically induced. Survival Analysis. Time Factors. Treatment Outcome


20. Oktay K, Buyuk E, Rosenwaks Z, Rucinski J: A technique for transplantation of ovarian cortical strips to the forearm. Fertil Steril; 2003 Jul;80(1):193-8
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENT(S): One patient with stage IIIB squamous cell cervical carcinoma and one patient with recurrent benign ovarian cysts.
  • INTERVENTION(S): Preparation of thin ovarian cortical slices and transplantation under the skin of the forearm.
  • The first patient developed a dominant follicle 10 weeks after transplantation, and her gonadotropin levels decreased to nonmenopausal levels.
  • CONCLUSION(S): Heterotopic transplantation of ovarian tissue to the forearm is a simple and promising technique to restore ovarian function in women who become menopausal due to chemotherapy, surgery, or radiation.
  • [MeSH-major] Ovary / transplantation. Tissue Transplantation / methods
  • [MeSH-minor] Adult. Arm. Estradiol / blood. Female. Follicle Stimulating Hormone / blood. Humans. Luteinizing Hormone / blood. Oocytes. Ovariectomy. Progesterone / blood. Transplantation, Autologous / methods

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12849823.001).
  • [ISSN] 0015-0282
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


21. Beri R, Rosen FR, Pacini MJ, Desai SR: Severe dermatologic reactions at multiple sites after paclitaxel administration. Ann Pharmacother; 2004 Feb;38(2):238-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE SUMMARY: A 53-year-old white male with cancer of the base of the tongue was treated with paclitaxel 100 mg/m2 infused over 3 hours and carboplatin dosed at an AUC of 6 mg/mL x min infused over 30 minutes via a peripheral vein on the left arm.
  • After 4 doses of paclitaxel, the patient developed erythematous patches on both forearms and both thighs.
  • The lesions on the left arm worsened into a necrotic ulcer, exposing underlying tissues.
  • Our patient had dermatologic toxicity at the infusion site, as well as at multiple other sites, that developed about 6 weeks after the first paclitaxel infusion.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Paclitaxel / adverse effects. Skin Ulcer / chemically induced
  • [MeSH-minor] Carcinoma, Squamous Cell / drug therapy. Humans. Male. Middle Aged. Tongue Neoplasms / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14742758.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


22. Itoh Y, Ninomiya Y, Henta T, Tajima S, Ishibashi A: Topical delta-aminolevulinic acid-based photodynamic therapy for Japanese actinic keratoses. J Dermatol; 2000 Aug;27(8):513-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical delta-aminolevulinic acid-based photodynamic therapy for Japanese actinic keratoses.
  • Based on the opinion that 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) may be disadvantageous to Oriental patients with dark skin, including Japanese, because the competing chromophore melanin inhibits the photochemical reaction, we assessed the therapeutic effects when Japanese AK were treated with ALA-PDT.
  • The cure rates of AK on the face including the neck and on extremities were 81.8% and 55.6%, respectively.
  • However, a larger number of treatment sessions were required.
  • In the red light range, incoherent light including 630 nm and 670 nm is superior to 630 nm laser light.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Keratosis / drug therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use. Precancerous Conditions / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Arm. Asian Continental Ancestry Group / genetics. Facial Dermatoses / drug therapy. Facial Dermatoses / genetics. Female. Humans. Japan. Leg. Male. Neck. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10989575.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


23. Gujral MS, Patnaik PM, Kaul R, Parikh HK, Conradt C, Tamhankar CP, Daftary GV: Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers. Cancer Chemother Pharmacol; 2001 Jul;47 Suppl:S23-8
Hazardous Substances Data Bank. CHYMOTRYPSIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers.
  • PURPOSE: Based on in vitro and on clinical evidence of protection against acute side effects of radiation, a prospective randomized, open study was performed to determine the efficacy of an oral proteolytic enzyme preparation in patients with head and neck cancer receiving conventional fractionated radiation therapy.
  • 60Co gamma-radiation was delivered at a standard daily radiation dose of 2 Gy in 25-35 fractions over a period of 6-7 weeks.
  • Patients assigned to the test group arm additionally received enzyme tablets orally t.i.d. starting 3 days prior to radiation therapy, and continuing up to 5 days after completion of the course of radiation therapy.
  • Patients in the control arm were not given any drug or placebo.
  • Acute radiation side effects were described as mucositis, skin reaction, dysphagia, and were graded at each visit during and after radiation therapy, following RTOG/EORTC criteria.
  • RESULTS: The severity (maximum extent) of acute radiation therapy side effects was significantly less in enzyme-treated patients than in control patients: mucositis (mean: 1.3 vs 2.2, P < 0.001), skin reaction (1.2 vs 2.4, P < 0.001) and dysphagia (1.4 vs 2.2, P < 0.001).
  • The duration of these side effects as well as the sum scores of side effects were also less in the study arm.
  • CONCLUSIONS: Combination of enzyme therapy with conventional fractionated radiation therapy was feasible and well-tolerated.
  • There was significant protection against acute side effects of radiation therapy in the study arm.
  • Not only was the severity of acute side effects less but the duration was shorter and the time to onset was also delayed.
  • Prospective randomized double-blind studies would verify this role of an oral enzyme therapy as standard co-medication with radiation therapy to the head and neck region.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Chymotrypsin / therapeutic use. Endopeptidases / therapeutic use. Head and Neck Neoplasms / radiotherapy. Papain / therapeutic use. Radiation Injuries / prevention & control. Radiation-Protective Agents / therapeutic use. Trypsin / therapeutic use
  • [MeSH-minor] Acute Disease. Deglutition Disorders / etiology. Deglutition Disorders / prevention & control. Drug Combinations. Humans. Male. Middle Aged. Prospective Studies. Radiotherapy / adverse effects. Skin / radiation effects. Stomatitis / etiology. Stomatitis / prevention & control

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11561868.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Radiation-Protective Agents; 60098-82-0 / chymotrypsin, papain, trypsin drug combination; EC 3.4.- / Endopeptidases; EC 3.4.21.1 / Chymotrypsin; EC 3.4.21.4 / Trypsin; EC 3.4.22.2 / Papain
  •  go-up   go-down






Advertisement